Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis.
Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in cancer patients. However, ICIs are associated with significant immune-related adverse events (irAEs) and the underlying biological mechanisms are not well-understood. To ensure safe cancer treatment, research efforts are needed to comprehensively detect and understand irAEs.
Author(s): Wang, QuanQiu, Xu, Rong
DOI: 10.1093/jamiaopen/ooy045